Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 10/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 5/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.45 |
| ▸ | PRKCG | P05129 | 5/20 | 0.45 |
| ▸ | PRKCB | P05771 | 5/20 | 0.45 |
| ▸ | PRKCA | P17252 | 5/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.45 |
| ▸ | PRKCH | P24723 | 5/20 | 0.45 |
| ▸ | CDK2 | P24941 | 5/20 | 0.45 |
| ▸ | PRKCI | P41743 | 5/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.45 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.45 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090783 | 0.88 | CHEK1 (0.56) | CHEK1SMN1; SMN2PDPK1JAK1PIP5K1C | |
| SCHEMBL4096532 | 0.88 | FLT3 (0.43) | CHEK1SMN1; SMN2PDPK1PARP1PBK | |
| SCHEMBL13849227 | 0.83 | CHEK1 (0.55) | CHEK1SMN1; SMN2PDPK1JAK1PIP5K1C | |
| SCHEMBL13849194 | 0.79 | FLT3 (0.47) | CHEK1PDPK1FLT3 | |
| SCHEMBL13849195 | 0.78 | JAK1 (0.51) | CHEK1SMN1; SMN2JAK1 | |
| SCHEMBL4104292 | 0.78 | CHEK1 (0.47) | CHEK1SMN1; SMN2PDPK1PIP5K1CFLT3 | |
| SCHEMBL13849193 | 0.78 | FLT3 (0.52) | CHEK1SMN1; SMN2PDPK1FLT3 | |
| SCHEMBL4104351 | 0.78 | FLT3 (0.56) | CHEK1PDPK1FLT3 | |
| SCHEMBL12105176 | 0.78 | PDPK1 (0.48) | CHEK1SMN1; SMN2PDPK1PIP5K1CFLT3 | |
| SCHEMBL13849196 | 0.76 | CHEK1 (0.45) | CHEK1PDPK1PIP5K1CFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | PDK1, CHEK1, PDK3 | CHEK1 2/4885SMN1; SMN2 3412/4885PDPK1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.